Dear Danny,

BioScience Communications is working together with Pfizer Inc, the
makers of VIAGRA® (sildenafil citrate), to help people and doctors
learn more about erectile dysfunction (ED). We have a new information
only program in which we are reaching out to some of the most engaged
talkers about erectile dysfunction online and inviting them to join our
VIAGRA® (sildenafil citrate) Expert Consumers Forum. It is a password
protected site that will contain useful information on ED, and new
developments in research.  We would like to invite you to become a
member.  If you are interested just let us know and we will forward you
a user name and password.  Also, if there is anyone else you think
would be interested, please feel free to forward the message below.

Thank you for your time and interest.

Sincerely,

ED TEAM

_____________________________________________________________________
We are BiosScience Communications, a medical education and
communications company, working together with Pfizer, the makers of
VIAGRA® (sildenafil citrate) to help patients and doctors learn about
ED treatments. Please forgive the intrusion, but we have been
researching online information about VIAGRA® (sildenafil citrate) and
recognize that discussion forums can be a great patient-to-patient
education resource. Our team is impressed with the information and
conversations that take place here.

We work closely with Pfizer's ED experts - health care
professionals and consumers - and we would like to invite you to join
our VIAGRA® (sildenafil citrate) Expert Consumers Forum.  This is not
an advertisement but an invitation to explore information in our forum.

The VIAGRA® (sildenafil citrate) Expert Consumers Forum is an
exclusive new resource for people like you, influencers who share
high-quality comments and provide emotional support. Please let us know
if you would be interested in learning more about our expert consumers
forum and having access to ED information only available from Pfizer
Inc.

Sign up now by replying to this email at
EDteam@pfizerexpertconsumersforum.com to set up your username and
password. We look forward to hearing from you.

Sincerely,

BioScience ED Team

The health information contained herein is provided for educational
purposes only and is not intended to replace discussions with a
healthcare provider. The products discussed herein may have different
product labeling in different countries. All decisions regarding
patient care must be made with a healthcare provider, considering the
unique characteristics of the patient.

VIAGRA® (sildenafil citrate) is a medicine used to treat erectile
dysfunction (ED).

The use of VIAGRA ® (sildenafil citrate) and organic nitrates in any
form, at any time, is contraindicated.

Before treating ED, physicians should consider the impact of resuming
sexual activity and the mild and transient vasodilatory effects of
VIAGRA® (sildenafil citrate) on blood pressure. Physicians should
carefully consider whether patients with underlying cardiovascular
disease or other more unusual conditions could be adversely affected by
vasodilatory effects, especially in combination with sexual activity.

Patients with the following characteristics (recent serious
cardiovascular events, hypotension or uncontrolled hypertension, or
retinitis pigmentosa) did not participate in pre-approval clinical
trials. In these patients, physicians should prescribe VIAGRA®
(sildenafil citrate) with caution.

In a controlled interaction study of VIAGRA® (sildenafil citrate) and
amlodipine, the mean additional reduction in supine blood pressure was
8 mm Hg systolic and 7 mm Hg diastolic. When the alpha blocker
doxazosin (4 mg) and VIAGRA® (sildenafil citrate) (25mg) were
administered simultaneously to patients with BPH, mean additional
reductions of supine blood pressure of 7 mm Hg systolic and 7 mm Hg
diastolic were observed. When higher doses of VIAGRA® (sildenafil
citrate) and doxazosin (4 mg) were administered simultaneously, there
were infrequent reports of patients who experienced symptomatic
postural hypotension within 1 to 4 hours of dosing. Doses of 50 mg or
100 mg of VIAGRA® (sildenafil citrate) not be taken within 4 hours of
alpha-blocker administration. A 25 mg dose of VIAGRA® (sildenafil
citrate) may be taken at any time.

The most common side effects of VIAGRA® (sildenafil citrate) were
headache (16%), flushing (10%), and dyspepsia (7%). Adverse events,
including visual effects (3%), were generally transient and mild to
moderate.

As there have been infrequent reports of prolonged erections lasting
more than 4 hours or priapism, patients should be advised to seek
immediate medical attention should these occur.

Use of VIAGRA® (sildenafil citrate) offers no protection against
sexually transmitted diseases, including the human immunodeficiency
virus (HIV); therefore, physicians should consider counseling their
patients about protective measures.

Use a starting dose of 25 mg for a patient who may have increased
plasma levels (age>65, hepatic impairment, severe renal impairment, and
concomitant use of potent CYP450 3A4 inhibitors). Patients taking
ritonavir should not exceed 25 mg in a 48-hour period.

Please see full prescribing information for VIAGRA® (sildenafil
citrate) (25-mg, 50-mg, 100-mg) tablets.

Brought to you by Pfizer

http://www.pfizer.com/copyrightfrm.html
http://www.pfizer.com/privacyfrm.htm
http://www.viagramd.com/general/contactUs.asp
http://www.viagramd.com/general/siteMap.asp

This information is intended for residents of the United States. The
blue diamond tablet shape is a registered trademark of Pfizer Inc.